Intellect Neurosciences 10-Q 19 Nov 13 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 30, 2013	Nov. 19, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Intellect Neurosciences, Inc.	'
Entity Central Index Key	'0001337905	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'ILNS	'
Entity Common Stock, Shares Outstanding	'	317,715,676
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Jun. 30, 2013
ASSETS	'	'
Cash and cash equivalents	$20,286	$5,138
Total current assets	20,286	5,138
Security deposits	4,715	4,715
Total Assets	25,001	9,853
LIABILITIES AND CAPITAL DEFICIENCY	'	'
Accounts payable and accrued expenses	2,451,661	2,487,410
Accrued interest - convertible promissory notes	575,044	482,298
Derivative instruments	6,767,854	3,833,457
Preferred stock liability	172,874	172,874
Preferred stock dividend payable	6,041,622	5,350,503
Total Current liabilities	16,009,055	12,326,542
Long Term Debt	'	'
Convertible promissory notes	1,511,391	1,231,737
Total Liabilities	17,520,446	13,558,279
Capital deficiency:	'	'
Common stock, par value $0.001 per share, 2,000,000,000 shares authorized; 261,015,899 and 209,015,899 issued and outstanding at September 30, 2013, and June 30, 2013, respectively	261,016	209,016
Additional paid in capital	70,232,498	70,134,497
Deficit accumulated during the development stage	-87,988,985	-83,891,966
Total Capital Deficiency	-17,495,445	-13,548,426
Total Liabilities and Capital Deficiency	25,001	9,853
Series B Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	19	20
Series D Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	5	5
Series E Convertible Preferred Stock [Member]	'	'
Capital deficiency:	'	'
Convertible Preferred stock	$2	$2

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2013	Jun. 30, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	261,015,899	209,015,899
Common stock, shares outstanding	261,015,899	209,015,899
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	106,878	106,878
Preferred stock, liquidated (in dollars)	$1,870,380	$1,870,380
Series C Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	18,765	19,790
Preferred stock, liquidated (in dollars)	18,765,000	19,790,000
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	4,641	5,466
Preferred stock, liquidated (in dollars)	4,641,000	5,466,000
Series E Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	2,000	2,000
Preferred stock, liquidated (in dollars)	$2,000,000	$2,000,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended				101 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013
Revenues:	'		'		'
License fees	$0		$0		$10,516,667
Total revenue	0		0		10,516,667
Costs and Expenses:	'		'		'
Research and development	9,479		167,920		14,664,568
General and administrative	357,123		379,407		45,712,308
Total cost and expenses	366,602		547,327		60,376,876
Loss from operations	-366,602		-547,327		-49,860,209
Other income/(expenses):	'		'		'
Interest expense	-3,736,878		-877,722		-73,671,742
Interest income	0		0		18,525
Changes in value of derivative instruments and preferred stock liability	6,461		1,278,781		44,539,854
Loss on extinguishment of debt	0		0		-627,809
Other	0		0		-6,587,604
Write off of investment	0		0		-150,000
Total other income/(expense):	-3,730,417		401,059		-36,478,776
Net loss	-4,097,019		-146,268		-86,338,985
Deemed preferred stock dividend	0		0		1,650,000
Net loss allocable to Common Shareholders	($4,097,019)		($146,268)		($87,988,985)
Basic loss per share (in dollars per share)	($0.02)	[1]	$0	[1]	'
Diluted loss per share (in dollars per share)	($0.02)		$0		'
Weighted average number of shares outstanding:	'		'		'
Basic (in shares)	230,102,856		103,321,542		'
Diluted (in shares)	230,102,856		103,321,542		'
[1]	For the quarter ended September 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		101 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cashflows from operating activities:	'	'	'
Net loss	($4,097,019)	($146,268)	($87,988,985)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation and amortization	0	'	836,769
Amortization of financing costs	0	'	2,403,966
Change in unrealized (gain) loss of derivative instruments	-6,461	-1,278,781	-43,837,993
Stock and warrant based compensation	150,000	231,265	18,237,586
Interest expense related to warrants	2,406,945	137,567	46,825,988
Write-off of investment	0	0	150,000
Shares issued in connection with merger	0	0	7,020,000
Shares issued for note extensions and compensation	0	'	753,453
Conversion of common stock to new Series B preferred shares	0	0	6,606,532
Non-cash interest expense	1,329,933	740,155	21,444,191
Non-cash expense related to Series B dividends	0	0	1,802,610
Disposition of fixed assets	0	0	43,412
Loss on sale of fixed assets	0	0	179,516
Loss on extinguishment of debt	0	0	-74,060
Changes in:	'	'	'
Prepaid expenses and other assets	0	8,066	-898
License fee receivable	0	0	-6,963
Accounts payable and accrued expenses	-35,750	-1,258	3,403,745
Other long term liabilities	0	0	-71,152
Net cash used in operating activities:	-252,352	-309,254	-22,272,284
Cashflows from investing activities:	'	'	'
Security deposit	0	0	-3,912
Acquisition of property and equipment	0	0	-1,059,699
Cash paid for acquisition	0	0	-150,000
Net cash used in investing activities:	0	0	-1,213,611
Cashflows from financing activities:	'	'	'
Borrowings from stockholders	0	0	6,153,828
Proceeds from sale of common stock	0	0	1,761,353
Proceeds from sale of preferred stock	0	0	7,711,150
Preferred stock issuance costs	0	0	-814,550
Proceeds from sale of Convertible Promissory Notes	267,500	360,000	12,391,500
Repayment of borrowings from stockholder	0	0	-1,706,000
Convertible Promissory Notes issuance cost	0	0	-466,100
Repayment of borrowings from noteholders	0	-32,500	-1,725,000
Proceeds from excersise of stock warrants	0	0	200,000
Net cash provided by financing activities:	267,500	327,500	23,506,181
Net increase in cash and cash equivalents	15,148	18,246	20,286
Cash and cash equivalents beginning of period	5,138	2,307	'
Cash and cash equivalents end of period	20,286	20,553	20,286
Supplemental disclosure of cash flow informations:	'	'	'
Interest	0	0	145,115
Non-cash investing and financing transactions:	'	'	'
Conversion of Convertible Notes payable and accrued interest into Common Stock (including derivative liability)	0	0	16,285,736
Conversion of Preferred Stock to Common Stock	37,000	5,000	6,897,451
Common Stock issued in repayment of debt	0	0	248,000
Accrued dividend on Series B prefs treated as capital contribution	0	0	387,104
Cashless exercise of Warrant for Common Stock	0	0	18,843,360
Debt discount from warrants and beneficial conversion feature	267,500	328,129	1,809,697
Deemed preferred stock dividend from beneficial conversion feature	0	0	1,650,000
Issuance of warrants for repayment of accrued expenses	$0	$560,000	$704,085

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Note 1. Basis of Presentation
	The accompanying unaudited consolidated condensed financial statements presented herein have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013 filed with the Securities and Exchange Commission (the “SEC”) on October 15, 2013. In the opinion of management, this interim information includes all material adjustments, which are of a normal and recurring nature, necessary for fair presentation.
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates that are particularly susceptible to change include assumptions used in determining the fair value of securities owned and non-readily marketable securities.
	The results of operations for the three months ended September 30, 2013, are not necessarily indicative of the results to be expected for the entire year or for any other period.

Business_Description_and_Going

Business Description and Going Concern	3 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	2. Business Description and Going Concern
	Intellect Neurosciences, Inc. (“Intellect”, “our”, “us”, “we” or the “Company” refer to Intellect Neurosciences, Inc. and its subsidiaries) a Delaware corporation, is a biopharmaceutical company, which together with its subsidiary Intellect Neurosciences, USA, Inc. (“Intellect USA”), is conducting research regarding proprietary drug candidates to treat Alzheimer’s disease (“AD”) and other diseases associated with oxidative stress. In addition, we have developed and are advancing a patent portfolio related to specific therapeutic approaches for treating AD. Since our inception in 2005, we have devoted substantially all of our efforts and resources to research and development activities and advancing our patent estate. We operate under a single segment. Our fiscal year end is June 30. We have had no product sales through September 30, 2013 though we have received $10,516,667 in up-front and milestone license fees from inception through September 30, 2013. Our losses from operations have been funded primarily with the proceeds of equity and debt financings and fees due under license agreements.
	We are a development stage company and our core business strategy is to leverage our intellectual property estate through license arrangements and to develop our proprietary compounds that we have purchased, developed internally or in-licensed from universities and others, through human proof of concept (Phase II) studies or earlier if appropriate and then seek to enter into collaboration agreements, licenses or sales to complete product development and commercialize the resulting drug products. Our objective is to obtain revenues from licensing fees, milestone payments, development fees and royalties related to the use of our intellectual property estate and the use of our proprietary compounds for specific therapeutic indications or applications. As of March 31, 2013, we had no self-developed or licensed products approved for sale by the U.S. Food and Drug Administration (“FDA”). There can be no assurance that our research and development efforts will be successful, that any products developed by any of our licensees will obtain necessary government regulatory approval or that any approved products will be commercially viable. In addition, we operate in an environment of rapid change in technology and are dependent upon the continued services of our current employees, consultants and subcontractors.
	We have limited capital resources and operations since inception have been funded with the proceeds from equity and debt financings and license fee arrangements. As of September 30, 2013, we had cash and cash equivalents of $20,286. We anticipate that our existing capital resources will enable us to continue operations for the next few months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential shareholders or partners within the next few months, we may be forced to cease operations.
	Our business will require substantial additional investment that we have not yet secured. We cannot be sure how much we will need to spend in order to develop new products and technologies in the future. Further, we will not have sufficient resources to develop fully any new products or technologies unless we are able to raise substantial additional financing on acceptable terms or secure funds from new or existing partners. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners, we will be unable to successfully develop and commercialize our products. We cannot assure you that financing will be available in a timely manner, on favorable terms or at all. No adjustment has been made to the carrying amount and classification of assets and the carrying amount of liabilities based on the going concern uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	3. Summary of Significant Accounting Policies
	Revenue Recognition
	Upfront License Fees. Consideration that we receive pursuant to patent license agreements is recognized as income when (a) the licensee obtains a license to one or more of our patents, (b) the licensee is responsible for all of the development work on the product candidate, (c) the licensee has the technical ability to perform the development, (d) the licensee requires a license from us to sell the resulting drug product without infringing our patents, (e) payment due under the license agreement is reasonably assured and (f) we have no future performance obligations under the license agreement.
	Milestones. We enter into patent license agreements, which contain milestones related to reaching particular stages in product development. We recognize revenues from milestones when we have no further obligation with respect to the activities under the agreement and when we have confirmed that the milestone has been achieved. Where we have continuing involvement obligations in the form of development efforts, we recognize revenues from milestones ratably over the development period.
	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect Israel, and the accounts of Mindgenix, Inc. (“Mindgenix”), a wholly-owned subsidiary of Mindset Biopharmaceuticals, Inc. (“Mindset”). We consolidate Mindgenix because we have agreed to absorb certain costs and expenses incurred by Mindgenix that are attributable to its research. Dr. Chain, our CEO, is a controlling shareholder of Mindset and the President of Mindgenix. All inter-company transactions and balances have been eliminated in consolidation
	Convertible Instruments. We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Purchase Warrants. We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	Preferred Stock. We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt. The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the three month periods ended September 30, 2013, we recognized other income of $6,461, relating to recording the derivative liabilities at fair value. At September 30, 2013 and June 30, 2013, there were $6,767,854 and $3,833,457 of derivative liabilities, respectively.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the quarter ended September 30, 2013:
	Estimated dividends:	None
	Expected volatility:	167%
	Risk-free interest rate:	1.76%
	Expected term (years):	0.5 to 5 years

ViroPharma_License_Transaction

ViroPharma License Transaction	3 Months Ended
	Sep. 30, 2013
License Transaction [Abstract]	'
License Transaction Disclosure [Text Block]	'
	4. ViroPharma License Transaction
	On and effective as of September 29, 2011, we entered into an Exclusive License Agreement (the “License Agreement”) with ViroPharma Incorporated, a Delaware corporation (“ViroPharma”), pursuant to which, among other things, we granted an exclusive license to ViroPharma regarding certain of our licensed patents and patent applications related to our clinical stage drug candidate, OX1, an antioxidant molecule containing indole-3-propionic acid. We expect ViroPharma to develop and commercialize OX1 as a treatment of Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
	Under the terms of the License Agreement, we agreed to transfer to ViroPharma all of our intellectual property rights, data and know-how related to our OX1 research and development program in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee which was received in October 2011, and additional regulatory milestone payments based upon defined events in the United States and the European Union. The aggregate maximum of these milestone payments assuming successful advancement of the product to market could amount to $120 million. In addition, ViroPharma will pay us a tiered royalty of up to an aggregate maximum of low double digits based on annual net sales. NYU School of Medicine and South Alabama Medical Science Foundation, which own certain patents in relation to OX1, are entitled to a portion of the royalties and revenues received by us from any sale or license of OX1 pursuant to an exclusive license agreement between the universities and us.
	The term of the License Agreement will continue in effect on a licensed product-by-licensed product and country-by-country basis until the expiration of the last royalty obligation with respect to a licensed product in such country. Once the royalty obligation has terminated in a particular country, the license will become non-exclusive and fully paid-up with respect to licensed products in that country.
	Either party may terminate the License Agreement upon an uncured material breach of the other party. In addition, if ViroPharma determines that it is not feasible or desirable to develop or commercialize licensed products, it may terminate the License Agreement in whole or on a product-by-product basis at any time upon ninety (90) days prior written notice to us. In the event of a termination of the License Agreement, other than ViroPharma’s termination of the License Agreement for our uncured material breach, we will have an exclusive, perpetual, irrevocable, worldwide, royalty-bearing license to exploit the licensed products.

Notes_Payable

Notes Payable	3 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	5. Notes Payable
	The December 2010 Notes
	On December 15, 2010, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the “December 2010 Notes”), shares of Series C Convertible Preferred Stock (“Series C Prefs”) and warrants (the “December 2010 Warrants”). Total proceeds from the sale of these investment units were $500,000.
	The December 2010 Notes have an aggregate face amount of $500,000, are due on December 15, 2013 and bear interest at 14%, payable at maturity. Principal and accrued interest on the Notes are convertible into shares of our common stock at an initial conversion price of $.125 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. As a result of the ratchet provisions contained in the Notes, the holders are entitled to purchase up to 10 million shares of our Common Stock.
	The December 2010 Warrants initially entitle the holders to purchase up to a total of 4 million shares of our common stock at an initial exercise price of $0.125 per share. As a result of the ratchet provisions contained in the December 2010 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock at an exercise price of $0.001 per share. Also, we issued an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million, which, as a result of the ratchet provisions contained in the Certificate of Designation of series C Preferred Stock, are convertible into 200 million shares of our Common Stock at a conversion price of $0.05 per share.
	We allocated the $500,000 of proceeds to the December 2010 Notes and Series C Preferred shares based on their relative fair values at date of issuance, which resulted in an allocation of $25,000 and $475,000, respectively. We determined the initial fair value of the December 2010 Warrants to be $378,017 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the December 2010 Notes. Under authoritative guidance, the carrying value of the December 2010 Notes may not be reduced below zero. Accordingly, we recorded the excess of the value of the December 2010 Warrants over the allocated fair value of the December 2010 Notes as interest expense incurred at the time of issuance of the December 2010 Notes in the amount of $353,017.  The discount related to of the December 2010 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The guidance provided in ASC 470-20-30-5 has been applied to the amount allocated to the Series C Preferred Stock, and the effective conversion price has been used to measure the intrinsic value of the embedded conversion option, and limited to the amount of proceeds allocated to the convertible instrument.  The intrinsic value of the beneficial conversion feature was calculated by comparing the effective conversion price and the market price of the Company’s common stock on the date of issuance. The fair value of $475,000 of the beneficial conversion feature has been recognized as a deemed dividend on the preferred stock for the year ended June 30, 2011, since the Series C Preferred stock is immediately convertible upon issuance and has no stated redemption date.
	As a result of the “ratchet” provisions contained in the April 2010 Notes and outstanding Warrants, the conversion price of the remaining outstanding April 2010 Notes and exercise price of our outstanding Warrants and Series B Convertible Preferred Stock were adjusted to $0.001 per common share. The conversion price of previously issued and outstanding Series B Convertible Preferred Stock held by holders other than the purchasers of the April 2010 Notes is not subject to adjustment as a result of the issuance of the December 2010 Notes.
	In January 2011, as a result of the “ratchet” provisions contained in the April 2010 Notes, we issued to purchasers of the April 2010 Notes remaining outstanding an additional 2,000 shares of our Series C Prefs with an initial aggregate liquidation preference equal to $2 million, which are convertible into 40 million shares of our common stock at an exercise price of $0.001 per share. In addition, in May 2011, we issued 429,000 shares of our Common Stock as additional compensation to certain holders of the April 2010 Notes as a result of the “ratchet” provisions contained in those Notes.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “March 2011 Notes”
	On March 15, 2011, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the “March 2011 Notes”), shares of Series C Prefs and warrants (the “March 2011 Warrants”). Total proceeds from the sale of these investment units were $500,000.  The terms of the March 2011 Notes and Warrants are the same as the terms contained in the December 2010 Notes and Warrants.
	The March 2011 Notes have an aggregate face amount of $500,000, are due on March 15, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the Notes are convertible into shares of our common stock at an initial conversion price of $.125 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. As a result of the ratchet provisions contained in the March 2011Notes, the holders are entitled to purchase up to 10 million shares of our Common Stock.
	The March 2011 Warrants initially entitle the holders to purchase up to a total of 4 million shares of our common stock at an initial exercise price of $0.125 per share. As a result of the ratchet provisions contained in the March 2011 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock at an exercise price of $0.001 per share. Also, we issued an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million, which, as a result of the ratchet provisions contained in the Certificate of Designation of series C Preferred Stock, are convertible into 200 million shares of our Common Stock at a conversion price of $0.001 per share.
	We allocated the $500,000 of proceeds to the March 2011 Notes and Series C Prefs based on their relative fair values at date of issuance, which resulted in an allocation of $25,000 and $475,000, respectively. We determined the initial fair value of the March 2011 Warrants to be $378,017 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the March 2011 Notes. Under authoritative guidance, the carrying value of the March 2011 Notes may not be reduced below zero. Accordingly, we recorded the excess of the value of the March 2011Warrants over the allocated fair value of the March 2011 Notes as interest expense incurred at the time of issuance of the March 2011 Notes in the amount of $353,017.  The discount related to of the March 2011 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The guidance provided in ASC 470-20-30-5 has been applied to the amount allocated to the Series C Preferred Stock, and the effective conversion price has been used to measure the intrinsic value of the embedded conversion option, and limited to the amount of proceeds allocated to the convertible instrument.  The intrinsic value of the beneficial conversion feature was calculated by comparing the effective conversion price and the market price of the Company’s common stock on the date of issuance. The fair value of $475,000 of the beneficial conversion feature has been recognized as a deemed dividend on the preferred stock for the year ended June 30, 2011, since the Series C Preferred stock is immediately convertible upon issuance and has no stated redemption date.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “June and July 2011 Notes”
	On June 30, 2011, we sold investment units (“June 2011 Investment Units”) for an aggregate purchase price of $100,000. Each unit consisted of a Convertible Promissory Note (the “June 2011 Notes”) and warrants (the “June 2011 Warrants”). Total proceeds from the sale of these investment units were $100,000.
	The June 2011 Notes have an aggregate face amount of $100,000, are due on June 30, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the June 2011 Notes are convertible into shares of our common stock at an initial conversion price of $.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the June 2011 Notes. The June 2011 Warrants entitle the holders to purchase up to a total of 10 million shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the June 2011 Warrants to be $817,151 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the June 2011 Notes by $100,000 with the excess of $717,151 charged to interest expense. This difference was amortized over the term of the June 2011 Notes as interest expense, calculated using an effective interest method.
	During July and August, 2011, we sold additional investment units for an aggregate purchase price of $150,000. Each unit consisted of a Convertible Promissory Note (the “July 2011 Notes”) and warrants (the “July 2011 Warrants”). Total proceeds from the sale of these investment units were $150,000.
	The June 2011 Notes issued in July have an aggregate face amount of $150,000, are due on various dates during July and August, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the July 2011 Notes are convertible into shares of our common stock at an initial conversion price of $.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. The July 2011 Warrants entitle the holders to purchase up to a total of 20 million shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the July 2011 Warrants to be $1,626,973 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the July 2011 Notes by $150,000 with the excess of $1,476,973 charged to interest expense.
	In April 2012, we issued 500,000 shares of our common stock to one of the holders of July 2011 Notes upon his conversion of $25,000 principal amount due with respect to such Notes (Note 11.)
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “April and May 2012” Financing
	During April and May 2012, we sold investment units for an aggregate purchase price of $201,500. Each unit consisted of a Convertible Promissory Note (the April and May 2012 Notes”) and warrants (the “April and May 2012 Warrants”). Total proceeds from the sale of these investment units were $201,500.
	The April and May 2012 Notes have an aggregate face amount of $201,500, are due in April and May 2015 and bear interest at 14%, payable at maturity. Principal and accrued interest are convertible into shares of our common stock at an initial conversion price of $0.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalent by us at a price less than the effective conversion price of the April 2012 Notes. The April and May 2012 Warrants entitle the holders to purchase up to 25,150,000 shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the April and May 2012 warrants to be $1,100,650 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the April and May 2012 Notes by $201,500 with the excess of $899,150 charged to interest expense. The discount related to the April and May 2012 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	During July through November 2012, we sold additional investment units for an aggregate purchase price of $662,500. Each unit consisted of a Convertible Promissory Note and Warrants. Total proceeds from the sale of these investment units were $662,500.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	January 2013 Financing
	During January, February, March, and May through September 2013, we sold investment units for an aggregate purchase price of $771,000. Each unit consisted of a Convertible Promissory Note (the January 2013 Notes”) and warrants (the “January 2013 Financing Warrants”). Total proceeds from the sale of these investment units were $771,000.
	The January 2013 Notes have an aggregate face amount of $771,000, are due in January, February, March, and May through October 2016 and bear interest at 14%, payable at maturity. Principal and accrued interest are convertible into shares of our common stock at an initial conversion price of $0.01 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalent by us at a price less than the effective conversion price of the April 2012 Notes. The January 2013 Financing Warrants entitle the holders to purchase up to 515,000,000 shares of our Common Stock at an initial exercise price of $0.01 per share.
	We determined the initial fair value of the January 2013 Financing warrants to be $5,075,145 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the January 2013 Financing Notes by $771,000 with the excess of $4,304,145 charged to interest expense. The discount related to the January 2013 Financing Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The following table sets forth a summary of all of the outstanding convertible promissory notes at June 30, 2013:
	Convertible promissory notes issued	$	3,925,000
	Allocated to preferred stock		-950,000
	Accretion of notes allocated to preferred stock		820,899
	Notes repaid		-400,000
	Less amounts converted to common stock		-625,000
			2,770,899
	Less debt discount		1,259,508
	Balance September 30, 2013	$	1,511,391

Convertible_Preferred_Stock_an

Convertible Preferred Stock and Derivative Liability	3 Months Ended
	Sep. 30, 2013
Convertible Preferred Stock and Derivative Liability [Abstract]	'
Convertible Preferred Stock and Derivative Liability Disclosure [Text Block]	'
	6. Convertible Preferred Stock and Derivative Liability
	Series B Convertible Preferred Stock
	During the fiscal year ended June 30, 2007, we issued 459,309 shares of Series B Convertible Preferred Stock (the “Series B Prefs”). The shares carry a cumulative dividend of 6% per annum. The initial conversion price is 1.75 per share subject to certain anti-dilution adjustments. Each Series B Preferred share carries a stated value of $17.50 and is convertible into 10 shares of our Common Stock. We issued 3,046,756 warrants in connection with the issuance of the Series B Prefs (the “Series B Warrants”).
	Based on authoritative guidance, we accounted for the Series B Prefs and the Series B Warrants as derivative liabilities at the time of issuance using the Black Scholes option pricing model. We recorded the amount received in consideration for the Series B Prefs as a liability for the Series B Prefs with an allocation to the Series B Warrants and the difference recorded as additional paid in capital. The liability related to the Series B Prefs and the Series B Warrants will be marked to market for all future periods they remain outstanding with an offsetting charge to earnings.
	At June 30, 2013, the aggregate liquidation value of the Series B Prefs was $1,870,380, with a fair value of $172,874. As of June 30, 2013, we have accrued Series B Preferred Stock dividends payable of $576,934 which has been recognized as interest expense.
	As a result of the “ratchet” provisions contained in the Certificate of Designation of the Series B Prefs, the conversion price of the remaining Series B Prefs, as subsequently amended by a majority in interest of the holders of the series B Prefs, was reduced to $0.05 per common share as a result of the December 2010 Financing transaction described above. The conversion price of previously issued and outstanding Series B Prefs held by holders other than the purchasers of the April 2010 Notes is not subject to adjustment as a result of the issuance of the December 2010 Notes or March 2011 Notes.
	Series C Convertible Preferred Stock
	Effective December 15, 2010, our Board of Directors approved a Certificate of Designation of Series C Convertible Preferred Stock. Each share of Series C Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.05 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series C Preferred Stock. We issued to the purchasers of the December 2010 Notes 12,000 shares of our Series C Convertible Preferred Stock with an initial aggregate liquidation preference equal to $12 million, which are convertible into 240 million shares of our common stock.
	On March 15, 2011, we issued to certain purchasers of the March 2011 Notes an additional 10,000 shares of our Series C Convertible Preferred Stock with an initial aggregate liquidation preference equal to $10 million, which are convertible into 200 million shares of our common stock, in exchange for $500,000 (Note 5).
	During the quarter ended September 30, 2013, we issued 20,500,000 shares of our common stock to holders of Series C Preferred upon conversion of their shares.
	Series D Convertible Preferred Shares
	Effective October 24, 2010, our Board of Directors approved a Certificate of Designation of Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.05 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series D Preferred Stock. The Series D Preferred Stock was issued to holders of our warrants in exchange for cancellation of those warrants. The number of shares of Series D Preferred Stock issued to each warrant holder is an amount equal to the number of Series D Preferred Shares that would be convertible into an amount of common shares equal to 50% of the number of warrants held by such holder. Based on this formula, we issued 6,716 shares of Series D Preferred stock, which are convertible into 134,320,000 shares of our common stock.
	During the quarter ended September 30, 2013, we issued 16,500,000 shares of our common stock to holders of Series D Preferred upon conversion of their shares.
	Series E Convertible Preferred Shares
	Effective January 2, 2013, our Board of Directors approved a Certificate of Designation of Series E Convertible Preferred Stock. Each share of Series E Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.01 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series E Preferred Stock. The Series E Preferred Stock was issued to holders of royalty rights with respect to the Company’s anti-senilin patent estate (the “Royalty Rights”) in exchange for the Royalty Rights held by them. On January 2, 2013, we issued 2,000 shares of Series E Preferred stock, which are convertible into 200,000,000 shares of our common stock.
	The Company recognized this difference between the fair value per share of its common stock and the conversion price, multiplied by the number of shares issuable upon conversion. This Beneficial Conversion Feature of $700,000 was recorded as additional paid-in-capital for common shares, per EITF 98-5 “Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios”. The offsetting amount was amortizable over the period from the issue date to the first conversion date. Since the Series E Preferred Stock is immediately convertible, a deemed dividend of $700,000 to the Series E Preferred Stock was recorded and immediately amortized. As the Company is in an accumulated deficit position, the deemed dividend was charged against additional paid-in-capital for common shares, there being no retained earnings from which to declare a dividend. The net loss attributable to common shareholders reflects both the net loss and the deemed dividend

Outstanding_Warrants_and_Warra

Outstanding Warrants and Warrant Liability	3 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	7. Outstanding Warrants and Warrant Liability
	The “Series B Warrants”
	In connection with the issuance of the Series B Preferred, we issued Series B warrants to purchase up to 75,939 shares of our common stock. The initial exercise price of the Series B Warrants was $2.50 per common share, subject to anti-dilution adjustments. The strike price of the Series B Warrants was subsequently reduced to $1.75 per common share pursuant the anti-dilution adjustment. The Series B Warrants have a 5 year term.
	The Series B Warrants provide for cashless exercise under certain circumstances. Accordingly, the amount of additional shares underlying potential future issuances of Series B Warrants is indeterminate. There is no specified cash payment obligation related to the Series B Warrants and there is no obligation to register the common shares underlying the Series B Warrants except in the event that we decide to register any of our common stock for cash (“piggyback registration rights”). Presumably, we would be obligated to make a cash payment to the holder if we failed to satisfy our obligations under these piggyback registration rights. Based on authoritative guidance, we have accounted for the Series B Warrants as liabilities. As of September 30, 2013, a total of 2,857 Series B Warrants remain outstanding, with a strike price of $0.001 per share.
	The “April 2010 Warrants”.
	In connection with the April 2010 Financing, we issued a total of 1,546,667 Class A, 1,546,667 Class B and 1,546,667 Class C Warrants (collectively, the “April 2010 Warrants”). The Class A Warrants have a 5 year term, an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments and contain a “cashless exercise feature”. The Class B Warrants have a 9 month term and an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments. The Class C Warrants have a 5 year and 9 month term, an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments and contain a “cashless exercise feature”. The April 2010  Warrants provide the holder with “piggyback registration rights” as described above. Based on authoritative guidance, we have accounted for the April 2010  Warrants as liabilities. The liability, measured at fair value on the date of issuance using a Black-Scholes option pricing model has been offset by a reduction in the carrying value of the April 2010 Notes and will be marked to market for each future period they remain outstanding.
	On June 28, 2010, holders of 1,013,333 Class A Warrants exercised their Warrants through the cashless exercise feature and received a total of 11,000 shares of Company common stock.
	As a result of the “ratchet” provisions contained in the April 2010 Warrants, the number of warrants and the exercise price of the warrants are subject to adjustment as a result of the December 2010 Notes described above.
	On March 15, 2011 holders of 4 million Class B Warrants exercised their Warrants for cash and received a total of 4 million shares of our Common Stock.  The remaining Class B Warrants expired in January 2011.
	As of October 26, 2012, a total of 53,733,333 April 2010 A warrants were exchanged for Series D Preferred shares.
	“Consultant Warrants”
	In connection with the April 2010 Financing, we issued 700,000 warrants to various consultants (the “Consultant Warrants”) with terms that are the same as those contained in the Class A Warrants. Based on authoritative guidance, we have accounted for the Consultant  Warrants as liabilities.
	On June 28, 2010, holders of all of the outstanding Consultant Warrants exercised their Warrants through the cashless exercise feature and received a total of 11,000 shares of Company common stock.
	In August and October 2010, we issued an additional 6,000,000 warrants to consultants for investor relations and legal services. These warrants expire five years from the date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans. The terms of the warrants fail to specify a penalty if we fail to satisfy our obligation under these piggyback registration rights. Presumably we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for these consultant warrants as liabilities, measured at fair value, based on a Black-Scholes option pricing model.
	As of October 26, 2012, 6,000,000 Consultant Warrants were exchanged for Series D Preferred shares.
	“The December 2010 and March 2011 Warrants”
	In connection with the sale of the December 2010 Notes and March 2011 Notes, we issued warrants, we issued a total of 20,000,000 warrants (the “December 2010 and March 2011 Warrants”). These warrants expire five years from the date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans. The terms of the warrants fail to specify a penalty if we fail to satisfy our obligation under these piggyback registration rights. Presumably we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for these consultant warrants as liabilities, measured at fair value, based on a Black-Scholes option pricing model.
	As of October 26, 2012, 9,800,000 of December 2010 and March 2011 Warrants, were exchanged for Series D Preferred shares.
	The “June and July 2011 Warrants”
	In connection with the sale of the June Notes, we issued a total of 30 million warrants (the “June and July 2011 Warrants”). The June and July 2011 Warrants expire five years from date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the June and July Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the June and July 2011 Warrants as liabilities. The liability for the June and July 2011 Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of October 26, 2012, 30 million “June and July 2011” warrants were exchanged for Series D Preferred shares.
	The “2011 Director Warrants”
	In October 2011, we issued warrants to purchase 2,881,680 shares of our common stock to our former independent directors in partial satisfaction of outstanding fees owed to such directors (the “2011 Director Warrants”). The 2011 Director Warrants have a 5 year term, an initial exercise price of $0.05 per common share, subject to anti-dilution adjustments, and contain a “cashless exercise feature”. The 2011 Director Warrants provide the holder with “piggyback registration rights” as described above. Based on authoritative guidance, we have accounted for the 2011 Director Warrants as liabilities. The liability, measured at fair value on the date of issuance using a Black-Scholes option pricing model will be marked to market for each future period they remain outstanding. As of September 30, 2013 2,881,680 warrants are outstanding
	The “April and May 2012” Warrants
	In connection with the sale of the April and May 2012 Notes, we issued a total of 99,150,000 warrants (the “April and May 2012 Warrants”). The April and May 2012 Warrants expire five years from date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the April and May 2012 Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the April and May 2012 Warrants as liabilities. The liability for the April and May 2012 Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of October 26, 2012, 53,150,000 “April and May 2012” warrants were exchanged for Series D Preferred shares, while 46,000,000 warrants were outstanding as of December 31, 2012. On March 13, 2013, all of the outstanding warrants were exchanged for common stock in a cashless exercise and 29,525,879 shares of common stock were issued.
	The January 2013 Financing Warrants
	In connection with the sale of the January 2013 Notes, we issued a total of 515,000,000 warrants. The January 2013 Financing Warrants expire five years from date of issuance. The exercise price of each warrant is $0.01 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the January 2013 Financing Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the January 2013 Financing Warrants as liabilities. The liability for the January 2013 Financing Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of September 30, 2013, 515,000,000 warrants remain outstanding.

Capital_Deficiency

Capital Deficiency	3 Months Ended
	Sep. 30, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments Disclosure [Text Block]	'
	8. Capital Deficiency
	Common stock
	In August 2013, we issued 13,500,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In August 2013, we issued 15,000,000 shares of our common stock in consideration for services rendered to the Company, which was valued at $150,000.
	In September 2013, we issued 7,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In September 2013, we issued 16,500,000 shares of our common stock to holders of Series D Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.

Per_Share_Data

Per Share Data	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	9. Per Share Data
	The following table sets forth the information needed to compute basic earnings per share:
		Three Months Ended
		September 30.		September 30.
		2013		2012
	Basic EPS
	Net income (loss) attributable to common stockholders, basic	$	-4,097,019	$	-146,268
	Weighted average shares outstanding		230,102,856		103,321,542
	Basic income earnings per share (A)	$	-0.02	$	0
		(A)	For the quarter ended September 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Income_Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	10. Income Taxes
	No provision for income taxes has been recorded due to the utilization of net operating losses for which a 100% valuation allowance had been provided.

Subsequent_Events

Subsequent Events	3 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	11. Subsequent Events
	Management has evaluated events occurring after the date of these financial statements through the date these financial statements were issued. There were no material subsequent events as of that date other than disclosed below.
	On October 3, 2013, a holder of the Company’s Series C Convertible Preferred Stock converted $192,890 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 3,857,800 shares of the Company’s common stock.
	On October 9, 2013 we issued 19,500,000 shares of the Company’s common stock to a consultant for services rendered for the Company.
	On October 9, 2013, a holder of the Company’s Series D Convertible Preferred Stock converted $265,111 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 5,302,222 shares of the Company’s common stock.
	On October 31, 2013, a holder of the Company’s Series C Convertible Preferred Stock converted $242,835 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 4,856,700 shares of the Company’s common stock.
	On October 31, 2013, holders of convertible promissory notes converted their notes and all of their accrued interest into 13,183,055 shares of the Company’s common stock
	During October, 2013, we sold investment units for an aggregate purchase price of $75,000. Each unit consisted of a Convertible Promissory Note and warrants under the same terms as the January 2013 Financing. Total proceeds from the sale of these investment units were $75,000.
	On November 1, 2013, a holder of the Company’s Series D Convertible Preferred Stock converted $500,000 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 10,000,000 shares of the Company’s common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Upfront License Fees. Consideration that we receive pursuant to patent license agreements is recognized as income when (a) the licensee obtains a license to one or more of our patents, (b) the licensee is responsible for all of the development work on the product candidate, (c) the licensee has the technical ability to perform the development, (d) the licensee requires a license from us to sell the resulting drug product without infringing our patents, (e) payment due under the license agreement is reasonably assured and (f) we have no future performance obligations under the license agreement.
	Milestones. We enter into patent license agreements, which contain milestones related to reaching particular stages in product development. We recognize revenues from milestones when we have no further obligation with respect to the activities under the agreement and when we have confirmed that the milestone has been achieved. Where we have continuing involvement obligations in the form of development efforts, we recognize revenues from milestones ratably over the development period
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect Israel, and the accounts of Mindgenix, Inc. (“Mindgenix”), a wholly-owned subsidiary of Mindset Biopharmaceuticals, Inc. (“Mindset”). We consolidate Mindgenix because we have agreed to absorb certain costs and expenses incurred by Mindgenix that are attributable to its research. Dr. Chain, our CEO, is a controlling shareholder of Mindset and the President of Mindgenix. All inter-company transactions and balances have been eliminated in consolidation
Debt, Policy [Policy Text Block]	'
	Convertible Instruments. We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Purchase Warrants [Policy Text Block]	'
	Common Stock Purchase Warrants. We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	'
	Preferred Stock. We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
Derivatives, Policy [Policy Text Block]	'
	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt. The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the three month periods ended September 30, 2013, we recognized other income of $6,461, relating to recording the derivative liabilities at fair value. At September 30, 2013 and June 30, 2013, there were $6,767,854 and $3,833,457 of derivative liabilities, respectively.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the quarter ended September 30, 2013:
	Estimated dividends:	None
	Expected volatility:	167%
	Risk-free interest rate:	1.76%
	Expected term (years):	0.5 to 5 years

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Derivative Instruments [Table Text Block]	'
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the quarter ended September 30, 2013:
	Estimated dividends:	None
	Expected volatility:	167%
	Risk-free interest rate:	1.76%
	Expected term (years):	0.5 to 5 years

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
	The following table sets forth a summary of all of the outstanding convertible promissory notes at June 30, 2013:
	Convertible promissory notes issued	$	3,925,000
	Allocated to preferred stock		-950,000
	Accretion of notes allocated to preferred stock		820,899
	Notes repaid		-400,000
	Less amounts converted to common stock		-625,000
			2,770,899
	Less debt discount		1,259,508
	Balance September 30, 2013	$	1,511,391

Per_Share_Data_Tables

Per Share Data (Tables)	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the information needed to compute basic earnings per share:
		Three Months Ended
		September 30.		September 30.
		2013		2012
	Basic EPS
	Net income (loss) attributable to common stockholders, basic	$	-4,097,019	$	-146,268
	Weighted average shares outstanding		230,102,856		103,321,542
	Basic income earnings per share (A)	$	-0.02	$	0
		(A)	For the quarter ended September 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Business_Description_and_Going1

Business Description and Going Concern (Details Textual) (USD $)	3 Months Ended		101 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2012
License fees	$0	$0	$10,516,667	'	'
Cash and cash equivalents	$20,286	$20,553	$20,286	$5,138	$2,307

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended
	Sep. 30, 2013
Estimated dividends	'None
Expected volatility	167.00%
Risk-free interest rate	1.76%
Minimum [Member]	'
Expected term (years)	'6 months
Maximum [Member]	'
Expected term (years)	'5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013
Derivative, Gain (Loss) on Derivative, Net, Total	$6,461	'
Derivative Liabilities	$6,767,854	$3,833,457

ViroPharma_License_Transaction1

ViroPharma License Transaction (Details Textual) (USD $)	3 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Oct. 31, 2011
	Maximum [Member]	Virophrma [Member]
Payment For Up Front Licensing Fee	$120	$6.50
License Agreement Termination Description	'	'at any time upon ninety (90) days prior written notice to us

Notes_Payable_Details

Notes Payable (Details) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013
Convertible promissory notes issued	$3,925,000	'
Allocated to preferred stock	-950,000	'
Accretion of notes allocated to preferred stock	820,899	'
Notes repaid	-400,000	'
Less amounts converted to common stock	-625,000	'
Long-term Debt, Gross	2,770,899	'
Less debt discount	1,259,508	'
Balance September 30, 2013	$1,511,391	$1,231,737

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

Sep. 30, 2013

Dec. 15, 2010

31-May-11

Jan. 31, 2011

Sep. 30, 2013

Jun. 30, 2011

Dec. 31, 2010

Dec. 15, 2010

Dec. 15, 2010

Sep. 30, 2013

Dec. 15, 2010

Mar. 15, 2011

Sep. 30, 2013

Jun. 30, 2011

Mar. 15, 2011

Sep. 30, 2013

Mar. 15, 2011

Jun. 30, 2011

Jun. 30, 2011

Apr. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes December 2010 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes March 2011 [Member]

Convertible Promissory Notes June 2011 [Member]

Convertible Promissory Notes June 2011 [Member]

Convertible Promissory Notes July 2011 [Member]

Convertible Promissory Notes July 2011 [Member]

Convertible Promissory Notes July 2011 [Member]

Convertible Promissory Notes April and May 2012 [Member]

Convertible Promissory Notes April and May 2012 [Member]

Convertible Promissory Notes July August and September 2012 [Member]

Convertible Promissory Notes January 2013 [Member]

Convertible Promissory Notes January 2013 [Member]

Convertible Series C Preferred Stock [Member]

Convertible Series C Preferred Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Convertible Series C Preferred Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Debt Instrument, Face Amount

'

$500,000

'

'

'

'

'

'

'

'

'

$500,000

'

'

'

'

'

$100,000

'

'

$150,000

'

$201,500

'

$662,500

$771,000

'

Debt Instrument, Interest Rate During Period

'

14.00%

'

'

'

'

'

'

'

'

'

14.00%

'

'

'

'

'

14.00%

'

'

14.00%

'

14.00%

'

'

14.00%

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

817,151

'

'

1,626,973

'

1,100,650

'

'

5,075,145

Face Amount Of Investment Units Sold

'

500,000

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

100,000

'

'

150,000

'

201,500

'

'

771,000

'

Proceeds From Investment Units Sold

'

500,000

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

100,000

'

'

150,000

'

201,500

'

662,500

771,000

'

Debt Instrument, Convertible, Conversion Price

'

$0.13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.13

$0.05

'

'

$0.05

'

$0.05

'

'

$0.01

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.05

0.125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.05

'

'

0.05

'

0.05

'

'

0.01

'

Common Stock, Capital Shares Reserved for Future Issuance

'

10,000,000

'

'

'

'

'

'

'

'

4,000,000

10,000,000

'

'

200,000,000

'

4,000,000

10,000,000

'

'

20,000,000

'

25,150,000

'

'

515,000,000

'

Share Price

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, liquidated (in dollars)

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

Price Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares

'

$0.05

'

'

'

'

'

'

'

'

'

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Investment Units Sold Allocated To Notes Payable

'

'

'

'

25,000

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Investment Units Sold Allocated To Series C Preferred Stock

'

'

'

'

475,000

'

'

'

'

'

'

'

475,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Debt

'

'

'

'

353,017

'

'

'

'

378,017

'

'

353,017

'

'

378,017

'

717,151

'

'

1,476,973

'

899,150

'

'

4,304,145

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

'

'

'

'

475,000

'

'

'

'

'

'

'

475,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Revised Price Of Common Stock Shares To Be Issued Upon Conversion Of Series B Preferred Shares

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Series C Preferred Stock Shares Issued As Per Ratchet Provisions

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidation Preference Value Of Additional Series C Preferred Stock Shares Issued As Per Ratchet Provisions

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Number Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares As Per Ratchet Provisions

'

'

'

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price Of Additional Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares As Per Ratchet Provisions

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Common Stock Shares Issued As Per Ratchet Provisions

'

'

429,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease In Fair Value Of Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

150,000

'

201,500

'

'

771,000

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

'

'

'

'

Convertible_Preferred_Stock_an1

Convertible Preferred Stock and Derivative Liability (Details Textual) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

Jun. 30, 2013

Jun. 30, 2007

Sep. 30, 2013

Dec. 15, 2010

Sep. 30, 2013

Aug. 31, 2013

Jun. 30, 2013

Oct. 31, 2010

Sep. 30, 2013

Oct. 24, 2010

Jan. 31, 2013

Jan. 02, 2013

Jun. 30, 2013

Sep. 30, 2013

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Shares [Member]

Series D Convertible Preferred Shares [Member]

Series D Convertible Preferred Shares [Member]

Series E Convertible Preferred Shares [Member]

Series E Convertible Preferred Shares [Member]

December 2010 Notes [Member]

March 2011 Notes [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Stock Issued During Period, Value, New Issues

'

459,309

'

'

'

'

'

'

'

'

'

'

'

10,000

Preferred Stock, Dividend Rate, Percentage

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Initial Conversion Price Per Share

'

$1.75

'

$0.05

'

'

'

$0.05

'

'

$0.01

'

'

'

Convertible Preferred Stock, Total Shares Issued Upon Conversion

'

10

'

'

7,000,000

13,500,000

'

'

16,500,000

134,320,000

'

200,000,000

240,000,000

200,000,000

Issuance Of Warrants

'

3,046,756

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Stated Value Per Share

'

$17.50

'

$1,000

'

'

'

'

'

$1,000

'

$1,000

'

'

Preferred stock, liquidated (in dollars)

$1,870,380

'

$1,870,380

'

$18,765,000

'

$19,790,000

'

'

'

'

'

'

'

Preferred Stock Fair Value

172,874

'

'

'

'

'

'

'

'

'

'

'

'

500,000

Preferred Stock Aggregate Liquidation Preference Value

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

10,000,000

Convertible Preferred Stock Shares Issued

'

'

'

'

'

'

'

'

'

6,716

'

2,000

12,000

'

Dividends Payable

576,934

'

'

'

'

'

'

'

'

'

'

700,000

'

'

Reduced Conversion Price Per Share

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature

'

'

'

'

'

'

'

'

'

'

$700,000

'

'

'

Outstanding_Warrants_and_Warra1

Outstanding Warrants and Warrant Liability (Details Textual) (USD $)

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Oct. 26, 2012

Jan. 28, 2010

Sep. 30, 2013

Mar. 15, 2011

Sep. 30, 2013

Apr. 30, 2010

Sep. 30, 2013

Oct. 26, 2012

Jun. 28, 2010

Sep. 30, 2013

Oct. 26, 2012

Sep. 30, 2013

Oct. 26, 2012

Oct. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Mar. 13, 2013

Dec. 31, 2012

Oct. 26, 2012

Sep. 30, 2013

Series B Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

December 2010 and March 2011 Warrants [Member]

December 2010 and March 2011 Warrants [Member]

June and July 2011 Warrants [Member]

June and July 2011 Warrants [Member]

Director Warrants 2011 [Member]

Director Warrants 2011 [Member]

April and May 2012 Warrants [Member]

April and May 2012 Warrants [Member]

April and May 2012 Warrants [Member]

April and May 2012 Warrants [Member]

January 2013 Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class C Warrants [Member]

Issuance Of Warrants

'

75,939

1,546,667

'

'

1,546,667

'

1,546,667

'

'

'

'

20,000,000

'

30,000,000

'

'

'

99,150,000

'

'

'

515,000,000

Warrants Expiration, Term

'

'5 years

'5 years

'

'

'9 months

'

'5 years 9 months

'

'5 years

'

'

'5 years

'

'5 years

'

'5 years

'

'5 years

'

'

'

'5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.05

0.001

'

'

'

'

'

'

'

'

'

'

0.05

'

0.05

'

0.05

'

0.05

'

'

'

0.01

Class of Warrant or Right, Outstanding

'

2,857

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,881,680

'

'

46,000,000

'

515,000,000

Exercise Price Of Warrants

'

$2.50

$1.50

'

'

$1.50

'

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Strike Price Reduced Per Share

'

$1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Exercise Of Warrants

'

'

'

'

$1,013,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued Exercise Of Warrants

'

'

'

'

11,000

'

4,000,000

'

'

'

'

11,000

'

'

'

'

'

'

'

29,525,879

'

'

'

Issuance Of Warrants To Consultant

'

'

'

'

'

'

'

'

700,000

6,000,000

'

'

'

'

'

'

2,881,680

'

'

'

'

'

'

Cash Exercise Of Warrants

'

'

'

'

'

'

$4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exchanged For Preferred Shares

'

'

'

53,733,333

'

'

'

'

'

'

6,000,000

'

'

9,800,000

'

30,000,000

'

'

'

'

'

53,150,000

'

Capital_Deficiency_Details_Tex

Capital Deficiency (Details Textual) (USD $)	Sep. 30, 2013	Aug. 31, 2013	Sep. 30, 2013	Jun. 30, 2007	Aug. 31, 2013
	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	'	'	'	'	15,000,000
Stock Issued During Period, Value, Issued for Services	'	'	'	'	$150,000
Convertible Preferred Stock, Shares Issued Upon Conversion	7,000,000	13,500,000	16,500,000	10	'

Per_Share_Data_Details

Per Share Data (Details) (USD $)	3 Months Ended				101 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013
Basic EPS	'		'		'
Net income (loss) attributable to common stockholders, basic	($4,097,019)		($146,268)		($87,988,985)
Weighted average shares outstanding (in shares)	230,102,856		103,321,542		'
Basic income earnings per share (in dollars per share)	($0.02)	[1]	$0	[1]	'
[1]	For the quarter ended September 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended
	Sep. 30, 2013
Percentage Of Valuation Allowance For Operating Loss	100.00%

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	3 Months Ended					3 Months Ended			3 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Aug. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	October 9, 2013 [Member]	October 31, 2013 [Member]	October, 2013 [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
		Convertible Promissory Note [Member]	Convertible Promissory Note and Warrants [Member]			October 3, 2013 [Member]	October 31, 2013 [Member]		October 9, 2013 [Member]	November 1, 2013 [Member]
Conversion of Stock, Amount Converted	'	'	'	'	'	$192,890	$242,835	'	$265,111	$500,000
Convertible Preferred Stock Conversion Price Per Share	'	'	'	'	'	$0.05	$0.05	'	$0.05	$0.05
Convertible Preferred Stock, Total Shares Issued Upon Conversion	'	'	'	7,000,000	13,500,000	3,857,800	4,856,700	16,500,000	5,302,222	10,000,000
Face Amount Of Investment Units Sold	'	'	75,000	'	'	'	'	'	'	'
Proceeds From Investment Units Sold	'	'	$75,000	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	19,500,000	'	'	'	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	13,183,055	'	'	'	'	'	'	'	'